drugset / Trial / NCT03161288
A Study of KY1005 in Healthy Volunteers
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a single and multiple ascending dose, placebo-controlled, double-blind, Phase 1 study to evaluate the safety and tolerability of KY1005 in healthy volunteers.
Timeline
- Start
- 2017-05-29
- Primary completion
- 2018-03-30
- Completion
- 2018-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlitelimab | Monoclonal antibody | 0.006 mg/kg | — |
| Subject | Amlitelimab | Monoclonal antibody | 0.018 mg/kg | — |
| Subject | Amlitelimab | Monoclonal antibody | 0.05 mg/kg | — |
| Subject | Amlitelimab | Monoclonal antibody | 0.15 mg/kg | — |
| Subject | Amlitelimab | Monoclonal antibody | 0.45 mg/kg | — |
| Subject | Amlitelimab | Monoclonal antibody | 1.35 mg/kg | — |
| Subject | Amlitelimab | Monoclonal antibody | 4 mg/kg | — |
| Subject | Amlitelimab | Monoclonal antibody | 12 mg/kg | — |